This page shows the latest chemotherapy news and features for those working in and with pharma, biotech and healthcare.
achieved a “clinically meaningful reduction in the risk of death compared to chemotherapy”, although the trial wasn’t powered to detect statistical significance. ... which has not spread widely around the body after platinum chemotherapy or
Almost 70% of patients on the combination were still alive after 12 months, compared to 49% of the chemotherapy group. ... the response rate compared to chemotherapy in first-line NSCLC patients with a high tumour mutation burden (TMB).
on Keytruda (pembrolizumab) plus chemotherapy in this setting.
In January, the drug become the drug in the PD-1/PD-L1 class to improve overall survival when given in combination with chemotherapy in previously-untreated patients in the ... Roche’s Impower150 study of PD-L1 inhibitor Tecentriq (atezolizumab) plus
That means for now, PD1/PD-L1 inhibitors as monotherapy, or combined with chemotherapy or CTLA4 drugs like BMS’Yervoy (ipilimumab) “may end up continuing to be the dominant regimens”.
chemotherapy. The Swiss pharma group reported a 38% improvement in progression-free survival (PFS) data in the IMpower150 trial of Tecentriq (atezolizumab) and Avastin (bevacizumab) in non-small cell lung cancer ... The 1, 200 patient trial compared
More from news
Approximately 6 fully matching, plus 775 partially matching documents found.
After all, so many of today’s life-saving healthcare advances, from cancer chemotherapy to heart surgery, rely on effective antibiotics being available to prevent infections in patients.
Chemotherapy and Pharmacology, which concluded its treatment regimen showed ‘encouraging clinical benefit’.
In the case of cancer treatment, such drugs could also help to limit the use of traditional chemotherapy, which can be costly and have undesirable side effects.
As an ADC IMMU-132 contains SN-38, which is the active metabolite of the chemotherapy agent irinotecan, conjugated to an anti-TROP-2 antibody.
were thought to be a result of the chemotherapy regimen used to prepare the patients before administering the CAR T cell therapy.
More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.
affairs strategies and a strong expertise in oncology drug development that includes chemotherapy, immunology drugs and targeted agents across various tumour indications.
Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions
AP Pharma's lead product APF530 for the prevention of chemotherapy-induced nausea and vomiting.
AP Pharma appoints Dendreon’ s Jesse Hollingsworth to lead sales. Joins as company prepares to advance APF350 to treat side effects of chemotherapy. ... The appointment comes as AP Pharma prepares to advance its lead product APF350, which is intended
Bayer’ s former oncology head Robert Rosen joins AP Pharma. Will lead launch of drug to prevent chemotherapy-induced nausea. ... In this role he will lead efforts at the US-based specialty pharma company to launch APF530 – AP Pharma's lead product
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Febrile Neutropenia (FN) during adjuvant chemotherapy is associated with significant morbidity, mortality risk, and incremental costs. ... The client wanted a vendor to develop content for a Global Value Dossier (GVD) about the burden of febrile
Virtual reality as a distraction intervention for women receiving chemotherapy. Oncol Nurs Forum. ... 2012; 181:53– 7. Schneider SM, Kisby CK, Flint EP. Effect of virtual reality on time perception in patients receiving chemotherapy.
future. Industry commentators believe immuno-oncology to be the third major breakthrough in cancer treatment, following the early days of chemotherapy and the targeted treatments that followed on from them. ... Only by combining with traditional
This is very different to how we currently assess chemotherapies – by their response rates – where stable disease would be perceived as a poor response.
Also in cancers: chimeric antigen receptor T cell (CAR-T) therapy, a type of cancer immunology that could dismiss chemotherapy in some cancers, is now licensed in the US.
More from PMHub
Approximately 0 fully matching, plus 14 partially matching documents found.
infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...